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Abstract: Carbamazepine (CBZ) is an effective anticonvulsant that can sometimes cause 
hypersensitivity reactions that vary in frequency and severity. Strong associations have been 
reported between specific human leukocyte antigen (HLA) alleles and susceptibility to CBZ 
hypersensitivity reactions. Screening for HLA-B*15:02 is mandated in patients from South East 
Asia because of a strong association with Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN). HLA-A*31:01 predisposes to multiple phenotypes of CBZ hypersensitivity 
including maculopapular exanthema, hypersensitivity syndrome, and SJS/TEN in a range of 
populations including Europeans, Japanese, South Koreans and Han Chinese, although the 
effect size varies between the different phenotypes and populations. Between 47 Caucasians 
and 67 Japanese patients would need to be tested for HLA-A*31:01 in order to avoid a single 
case of CBZ hypersensitivity. A cost-effectiveness study has demonstrated that HLA-A*31:01 
screening would be cost-effective. Patient preference assessment has also revealed that patients 
prefer pharmacogenetic screening and prescription of alternative anticonvulsants compared to 
current standard of practice without pharmacogenetic testing. For patients who test positive for 
HLA-A*31:01, alternative treatments are available. When alternatives have failed or are unavail-
able, HLA-A*31:01 testing can alert clinicians to 1) patients who are at increased risk of CBZ 
hypersensitivity who can then be targeted for more intensive monitoring and 2) increase diag-
nostic certainty in cases where hypersensitivity has already occurred, so patients can be advised 
to avoid structurally related drugs in the future. On the basis of the current evidence, we would 
favor screening all patients for HLA-A*31:01 and HLA-B*15:02 prior to starting CBZ therapy.
Keywords: carbamazepine, oxcarbazepine, hypersensitivity, adverse drug reaction, pharma-
cogenetics, HLA
Introduction
Carbamazepine (CBZ) is an effective anticonvulsant that is also used the in the treatment 
of psychiatric disorders.1,2 However, it is associated with hypersensitivity reactions in up 
to 10% of patients.1 These reactions include severe conditions, such as toxic epidermal 
necrolysis (TEN), Stevens–Johnson syndrome (SJS), hypersensitivity syndrome (HSS) 
and milder reactions, such as maculopapular exanthema (MPE).3 The mortality rate of 
TEN at 1 year is 34%,4 and in pediatric patients who survived acute TEN, all patients 
suffered with long-term complications, which included scarring, visual loss and chronic 
kidney disease.5 Strong associations have been reported between specific human leu-
kocyte antigen (HLA) alleles and susceptibility to CBZ hypersensitivity reactions.6–8
HLA alleles are encoded by the major histocompatibility complex (MHC), are 
found in all vertebrates and are responsible for presentation of protein-derived peptides 
Correspondence: Munir Pirmohamed
MRC Centre for Drug Safety Science, 
Institute of Translational Medicine, 
Department of Molecular and 
Clinical Pharmacology, University 
of Liverpool, Block A: Waterhouse 
Building, 1-5 Brownlow Street, 
Liverpool, L69 3GL, UK
Tel +44 151 794 5557
Fax +44 151 794 5059
Email munirp@liverpool.ac.uk
Journal name: Pharmacogenomics and Personalized Medicine
Article Designation: REVIEW
Year: 2017
Volume: 10
Running head verso: Yip and Pirmohamed
Running head recto: HLA-A*3101 and carbamazepine therapy
DOI: http://dx.doi.org/10.2147/PGPM.S108598
Pharmacogenomics and Personalized Medicine 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Yip and Pirmohamed
to T cells as part of the adaptive immune response.9 There 
are two main classes of MHC molecules: class I (MHC-I) 
and class II (MHC-II). MHC-I molecules are encoded by 
three genes: HLA-A, HLA-B and HLA-C. Similarly, there 
are three MHC-II molecules called HLA-DR, HLA-DQ 
and HLA-DP.10 HLA genes constitute the most polymor-
phic gene cluster in the human genome with most allelic 
diversity concentrated in peptide binding sites of the HLA 
molecules enabling different alleles to bind a range of pep-
tides.10 Specific polymorphisms in HLA molecules have 
been associated with increased susceptibility to a number 
of hypersensitivity reactions affecting different organs and 
caused by a wide variety of therapeutically and structurally 
distinct drugs (Table 1).
CBZ-induced SJS/TEN has been strongly associated 
with carriage of HLA-B*15:02 in patients from South East 
Asian countries.6,11–15 A prospective cohort study in Taiwan 
demonstrated the clinical utility of pharmacogenetic screen-
ing for HLA-B*15:02 in preventing CBZ-induced SJS/
TEN.16 Regulatory agencies, such as the US Food and Drug 
Administration and the European Medicines Agency, have 
included warnings in the drug label and summary of product 
characteristic (SmPC), respectively, advising pharmacoge-
netic screening in patients from particular populations in 
South East Asia.17 The strong association of HLA-B*15:02 
with CBZ-induced SJS/TEN in South East Asian countries, 
but not in other countries, reflects the higher prevalence of 
this allele in those countries (Figure 1). Despite the fact that 
HLA-B*15:02 is rare in Caucasians (prevalence <0.01%), 
if a Northern European patient is positive for this allele, it 
would be important not to challenge the patient with CBZ,18 
although there is no specific evidence of the association in 
Caucasians.
HLA-A*31:01 has also been associated with CBZ-
induced hypersensitivity reactions in multiple populations 
including European and Japanese patients but pharmacoge-
netic screening is not currently mandated before initiation 
of CBZ therapy.7,8 It is included in a number of drug labels 
worldwide but the association with HLA-A*31:01 is men-
tioned for information only. Unlike HLA-B*15:02, which 
is largely restricted to South East Asia, HLA-A*31:01 is 
present in many different populations worldwide (Figure 1). 
The allele frequency of HLA-A*31:01 in European popula-
tions ranges between 2.1% and 3.6%. The frequency of 
HLA-A*31:01 varies across Asian populations: Han Chinese 
(2.8%–3.6%), Korean (5.6%) and Japanese (7.1%–12%). 
The highest frequencies have been reported in South Ameri-
can countries, such as Argentina (25%–38.6%) and Brazil 
(2.6%–18.5%; www.allelefrequencies.net).
This review aims to summarize the association between 
HLA-A*31:01 and CBZ hypersensitivity, evaluate the asso-
ciation studies that have been performed to date, discuss the 
proposed interaction between CBZ and HLA-A*31:01, iden-
tify the challenges in applying pharmacogenetic screening for 
HLA-A*31:01 and proposals for overcoming these barriers.
HLA-A*31:01 and CBZ 
hypersensitivity
Retrospective case–control studies in multiple patient popula-
tions have reported associations between HLA-A*31:01 and 
Table 1 A selection of HLA allele associations with drug-induced hypersensitivity reactions
Drug Class of drug HLA allele Hypersensitivity reaction References
Abacavir Antiretroviral B*57:01 AHS 52, 53
Allopurinol Xanthine oxidase inhibitor B*58:01 HSS 54, 55
SJS/TEN
Amoxicillin-Clavulanate Antibiotic DRB1*15:01 DILI 56, 57
A*02:01
B*18:01
Flucloxacillin Antibiotic B*57:01 DILI 58
Lamotrigine Anticonvulsant B*58:01 HSS 59
A*68:01 SJS/TEN
DRB1*13:01
Nevirapine Antiretroviral DRB1*01 DILI 60–62
B*35:05 MPE
C*04:01 HSS
SJS/TEN
Phenytoin Anticonvulsant B*15:02 SJS/TEN 11, 63
Abbreviations: AHS, abacavir hypersensitivity syndrome; DILI, drug-induced liver injury; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular 
exanthema; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.
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Figure 1 Allele frequency distribution for HLA-A*31:01 and HLA-B*15:02.
Notes: HLA-A*31:01 is widely distributed in comparison with HLA-B*15:02, which is predominantly concentrated in South East Asia. Adapted from Gonzalez-Galarza FF, 
Takeshita LY, Santos EJ, et al. New features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acid Research. 2015;28:D784–788.64
CBZ hypersensitivity (Table 2). The first association between 
HLA-A*31:01 and CBZ hypersensitivity was reported in Han 
Chinese patients from Taiwan.19 In this study, a significant 
association was reported between HLA-A*31:01 and CBZ-
induced MPE but not for SJS-TEN.
Subsequently, two independent genome-wide association 
studies (GWAS) in European and Japanese patients demon-
strated that carriage of HLA-A*31:01 was significantly asso-
ciated with all phenotypes of CBZ hypersensitivity.7,8 In the 
European study, HLA-A*31:01 was significantly associated 
with HSS (P=3.5×10−8) in a GWAS. Subsequent analyses of 
replication cohorts showed HLA-A*31:01 to be associated 
with all phenotypes of CBZ hypersensitivity: CBZ-induced 
SJS/TEN (n=12 cases, odds ratio [OR]=25.93 [95% confi-
dence interval [CI]: 4.93–116.18], P=8×10−5), HSS (n=27 
cases, OR=12.41 [95% CI: 1.27–121.03], P=0.03) and MPE 
(n=106 cases, OR=8.33 [95% CI: 3.59–19.36], P=8.0×10−7).7 
Similar results were reported in the Japanese GWAS with 
HLA-A*31:01 significantly associated with all phenotypes of 
CBZ hypersensitivity both individually and in pooled analysis 
(n=77 cases, OR=9.5 [95% CI: 5.6–16.3], P
c
=1.09×10−16).8 
The association between HLA-A*31:01 and all clinical 
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presentations of CBZ hypersensitivity in Japanese patients 
has been replicated in two further case–control studies.20,21
Subsequent studies have also investigated the association 
between HLA-A*31:01 and CBZ hypersensitivity in different 
populations. In Han Chinese, one study detected a significant 
association between HLA-A*31:01 and CBZ-induced MPE 
(n=18 cases, OR=17.5 [95% CI: 4.6–66.5], P
c
=2.2×10−3) but 
not HSS; however, only 13 patients with HSS were inves-
tigated.19 Another study in Han Chinese detected a strong 
association between HLA-A*31:01 and CBZ-induced HSS 
(n=10 cases; OR=26.3 [95% CI: 7.2–96.5], P<0.001) but no 
patients with MPE were included in this study.22 However, 
neither study showed an association between HLA-A*31:01 
and CBZ-induced SJS/TEN in Han Chinese patients,19,22 
where there is already a very strong association between 
HLA-B*15:02 and SJS/TEN. The molecular mechanisms by 
which HLA-B*15:02 predisposes to SJS/TEN only, whereas 
HLA-A*31:01 predisposes to several different phenotypes 
is not known, but may be a reflection of differences in the 
affinity and mechanisms of binding and antigen presentation 
in the two HLA alleles. Thus, if a patient is positive for both 
HLA-B*15:02 and HLA-A*31:01, binding to the former allele 
could be greater than to the latter, leading to the develop-
ment of SJS/TEN rather than another CBZ hypersensitivity 
phenotype. Clearly, this is a hypothesis which needs further 
investigation.
In Korean patients, a significant association for HLA-
A*31:01 was detected for CBZ-induced HSS (n=17 cases, 
OR=8.8 [95% CI: 2.5–30.7], P
c
=0.011), but not SJS/TEN; 
however, only 7 SJS/TEN patients were included, 3 of whom 
were positive for HLA-A*31:01.23 In Caucasian adults with 
CBZ-induced SJS/TEN only 3/20 subjects possessed HLA-
A*31:01 compared with 10/257 tolerant controls.22 The same 
study reported a strong association of HLA-A*31:01 with 
HSS (n=10 cases, OR=57.6 [95% CI: 11.0–340], P<0.001). 
A study in children with multiple ethnic backgrounds from 
Table 2 Studies investigating the association between HLA-A*31:01 and carbamazepine hypersensitivity
Study Population Adults/ 
children
Phenotype HLA allele  
positive number  
of patients
Carbamazepine 
tolerant  
controls
Odds ratio  
(95% confidence  
interval)
P-value
Hung et al19 Han Chinese  
(Taiwan)
Adults MPE 6/18 4/144 17.50 (4.6–66.5) Pc=2.2×10
−3
HSS 2/13 6.36 (1.2–33.9) NS
SJS/TEN 1/60 0.59 (0.1–4.1) NS
MPE and HSS 8/31 12.17 (3.6–41.2) Pc=0.0021
Kashiwagi et al20 Japanese (Japan) Adults MPE/HSS/SJS 11/22 53/371 4.33 (2.07–9.06) P<0.01
McCormack et al7 Caucasian  
(European)
Adults MPE 23/106 10/257 8.33 (3.59–19.36) P=8.0×10−7
HSS 10/27 12.41 (1.27–121.03) P=0.03
SJS 5/12 25.93 (4.93–116.18) P=8.0×10−5
All cADRs 38/145 9.12 (4.03–20.65) P=1.0×10−7
Ozeki et al8 Japanese (Japan) Adults Others incl. MPE 19/35 7/50 8.0 (3.9–16.6) Pc=4.74×10
−8
HSS 21/36 9.5 (4.6–19.5) Pc=2.06×10
−9
SJS/TEN 5/6 33.9 (3.9–295.6) Pc=2.35×10
−4
All cADRs 45/77 9.5 (5.6–16.3) Pc=1.09×10
−16
Kim et al23 Korean (Korea) Adults HSS 10/17 7/50 8.8 (2.5–30.7) Pc=0.011
SJS 3/7 4.6 (0.8–25.1) NS
HSS and SJS 13/24 7.3 (2.3–22.5) Pc=0.013
Niihara et al21 Japanese (Japan) Adults MPE/HSS/ 10/15 5/33 11.2 (2.668–47.105) P=0.001
SJS/TEN
Amstutz et al24 Multiple (Canada) Children MPE 6/26 3/91 8.57 (1.67–57.50) P=0.0037
HSS 3/6 26.36 (2.53–307.89) P=0.0025
SJS/TEN 0/9 1.33 (0.06–27.76) NS
HSS and MPE 9/32 11.18 (2.53–69.27) P=2.6×10−4
All cADRs 9/42 7.85 (1.82–47.8) P=0.0016
Genin et al22 Caucasian (Europe) Adults HSS 7/10 10/257 57.6 (11.0–340.0) P<0.001
SJS/TEN 3/20 NS NS
Han Chinese  
(Taiwan)
Adults HSS 5/10 3/72 26.3 (7.2–96.5) P<0.001
SJS/TEN 1/53 NS NS
Shirzadi et al26 Caucasian (Norway) Adults MPE/HSS 4/48 2/79 NS NS
Abbreviations: cADR, cutaneous adverse drug reaction; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome, MPE, maculopapular exanthema; NS, not 
significant; Pc, corrected P-value; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.
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Canada reported significant associations between HLA-
A*31:01 and CBZ-induced MPE (n=26 cases, OR=8.57 [95% 
CI: 1.67–57.50], P=0.0037) and HSS (n=6 cases, OR=26.36 
[95% CI: 2.53–307.89], P=0.0025).24 None of the 9 children 
presenting with SJS/TEN were positive for HLA-A*31:01.
Recently, the presence of the HLA-A*31:01 allele was 
confirmed in a familial case of CBZ-induced HSS.25 The 
index case, a 23-year-old Caucasian male, developed HSS 
after 2 weeks of CBZ therapy for epilepsy. Three months 
later, his mother also presented with symptoms compatible 
with HSS after 9 weeks of therapy with CBZ for trigeminal 
neuralgia. Carriage of HLA-A*31:01 was confirmed in both 
subjects with the authors advising other family members to 
avoid CBZ in the future.
The association between HLA-A*31:01 and CBZ hyper-
sensitivity was not detected in a population from Norway.26 
There were 48 cases of CBZ hypersensitivity in this study, 
but nearly all patients (43/48 [89.6%]) were diagnosed with 
MPE according to the phenotype standardization for immune-
mediated drug-induced skin injury guidance.27 A major issue 
with MPE is that causality determination is more difficult 
as many other factors including concomitant viral infections 
can cause mild cutaneous eruptions.
These studies confirm an association between carriage of 
HLA-A*31:01 and increased susceptibility to CBZ-induced 
hypersensitivity reactions. While the association with HSS 
seems clear from all the studies, whether HLA-A*31:01 
is also associated with MPE and SJS-TEN is more con-
troversial (Table 2). In Han Chinese patients, significant 
associations have been reported with MPE19 and HSS22 
but not SJS.22 In Japanese patients, the GWAS detected 
significant associations between HLA-A*31:01 and MPE, 
HSS and SJS/TEN.8 The original GWAS in Caucasian 
patients reported significant associations between carriage 
of HLA-A*31:01 and CBZ-induced MPE, HSS and SJS/
TEN.7 A subsequent study detected an association with HSS 
but not SJS,22 whereas the most recent study in a Norwegian 
population was unable to detect any association between 
HLA-A*31:01 and CBZ-induced MPE.26 The discrepancies 
in the studies are most likely to be due to a combination 
of small sample sizes, incorrect classification/diagnosis of 
cases and difficulty in determining causality particularly in 
milder cases. It is important to note that diagnosis of CBZ 
hypersensitivity reactions is complex because many patients 
are prescribed multiple medications preceding a reaction 
with diverse clinical presentations and variable times to 
onset of hypersensitivity, and the difficulty in excluding other 
nondrug etiologies.28 Standardized criteria for  classification 
of  drug-induced hypersensitivity reactions have been devel-
oped and should be used in clinical studies.27
HLA-A*31:01 and oxcarbazepine 
(OXC) hypersensitivity
OXC is a 10-keto analog of CBZ with an altered pharma-
cokinetic profile designed to reduce formation of reactive 
metabolites in comparison with CBZ.29 OXC has equal effi-
cacy to CBZ for seizure control, but may also have a reduced 
tendency to cause liver toxicity, anemia and agranulocytosis.30 
The incidence of cutaneous ADRs to OXC is lower than with 
CBZ.31 A study of 40 Korean patients with OXC-induced 
MPE identified 6 carriers of HLA-A*31:01 but the associa-
tion was not significant when compared with tolerant controls 
(OR=0.85 [95% CI: 0.29–2.48], P=1.000).32 The study also 
failed to identify an association between OXC-MPE and 
HLA-B*15:02. Other studies have included small numbers 
of patients with OXC, with some patients being positive for 
HLA-A*31:01.24 Taken together, the numbers of patients 
tested for HLA-A*31:01 who have had OXC hypersensitiv-
ity reactions are small, and no conclusions can be made at 
this stage as to whether this allele is a predisposing factor.
Pathophysiology of CBZ 
hypersensitivity reactions
Drug-induced hypersensitivity reactions are characterized by 
the activation of T cells by drugs or reactive metabolites.33 
The hapten hypothesis,34 direct pharmacologic interaction of 
drugs with immune receptors (PI)35 and the altered peptide 
repertoire model36 have been proposed as potential mecha-
nisms for activation of T cells by drugs (Figure 2).
In the hapten hypothesis chemically reactive small 
molecules, such as drugs or reactive metabolites, act as 
haptens to bind and irreversibly modify self-proteins. These 
modified proteins are recognized as antigens and presented 
in association with MHC to T-cell receptors (TCRs), lead-
ing to the activation of immune system and hypersensitiv-
ity.34 According to the PI model, small molecules, such as 
drugs, are able to bind directly and noncovalently to either 
the MHC or TCR to activate the immune system.37 In the 
altered peptide repertoire model, low molecular weight 
drugs bind to the antigen binding cleft of the HLA-class I 
molecules leading to conformational changes and an altered 
repertoire of peptides that are presented, which may now 
include self-peptides.36
Much of the research in CBZ hypersensitivity has focused 
on the interaction between HLA-B*15:02, CBZ and the 
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TCR. There is evidence to suggest that CBZ can activate 
the immune system via a combination of pathways. Reactive 
metabolites of CBZ, such as CBZ 10,11-epoxide, are able 
to modify serum proteins, such as human serum albumin, 
leading to the generation of chemically modified peptides 
that have the potential to activate the immune system via a 
hapten mechanism.38 CBZ is able to bind directly with HLA-
B*15:02 independent of intracellular metabolism or process-
ing consistent with a PI mechanism.39 Structural modeling 
suggests that CBZ is located at the interface between the 
HLA-B*15:02/peptide and TCR, with direct contact to the 
antigen peptide and bound within the TCR pocket.40 Further 
evidence to support direct interaction between CBZ and 
the TCR is the clonal expansion of specific TCRs observed 
in SJS/TEN patients compared with tolerant controls.41 
These CBZ-specific CD8+ T cells secrete granulysin and 
interferon-gamma, which mediate keratinocyte apoptosis in a 
HLA-B*15:02-dependent manner consistent with the known 
pathogenesis of SJS/TEN.41,42 Finally, preliminary studies 
suggest that binding of CBZ to HLA-B*15:02 may lead to 
an alteration of the repertoire of presented self-peptides36 
and activation of T cells only in the presence of endogenous 
peptides, but further work is needed to substantiate this.39
There have been very limited studies investigating the role 
of HLA-A*31:01 in CBZ hypersensitivity. A case study in a 
HLA-A*31:01 positive patient presenting with CBZ-induced 
MPE with eosinophilia and lymphocytosis demonstrated 
expansion of HLA-A*31:01 restricted CD8+ T-cell clones 
and DRB1*04:04 restricted CD4+ T-cell clones, indicat-
ing that a common HLA haplotype may contribute to the 
 multiclonal T-cell response seen in European patients with 
CBZ hypersenstivity.43 It is unclear at present why HLA-
B*15:02 predisposes to CBZ-induced SJS/TEN only, whereas 
HLA-A*31:01 is associated with multiple phenotypes of 
hypersensitivity. Further studies including larger numbers 
of patients who are carriers of HLA-A*31:01 are required to 
characterize the causal pathways.
Pharmacogenetic testing for 
HLA-A*31:01 prior to CBZ therapy
Pharmacogenetic testing for HLA-B*15:02 is recommended 
before initiation of CBZ therapy in patients of Asian origin.17 
The utility of genotype testing for HLA-B*15:02 has been 
confirmed in a prospective study in a Taiwanese population 
where pre-prescription genotyping reduced the incidence 
of CBZ-induced SJS/TEN from 10 expected cases to 0.16 
No prospective genotyping studies for HLA-A*31:01 have 
been published, although one is currently being undertaken 
in Japan.
Three systematic reviews have examined the association 
between HLA-A*31:01 and CBZ-induced hypersensitiv-
ity in multiple ethnic groups.3,22,44 A pooled analysis of all 
phenotypes of CBZ hypersensitivity and carriage of HLA-
A*31:01 reported a pooled OR=9.45 (95% CI: 6.41–13.93; 
P<0.00001).3 The second systematic review analyzed the 
association between HLA-A*31:01 and CBZ-induced HSS 
and SJS/TEN separately.22 A strong pooled OR=13.2 (95% 
CI: 8.4–20.8; P<0.00001) was reported for the association 
with HSS, whereas a weaker pooled OR=3.9 (95% CI: 
1.4–11.5; P=0.01) was reported for SJS/TEN.22 No patients 
A
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T-cell T-cell
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modified peptides on
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Figure 2 Proposed mechanisms of T-cell activation by drugs/drug metabolites.
Notes: (A) Hapten hypothesis: The hapten hypothesis postulates that a drug or its metabolite (yellow star) is able to bind covalently with self-proteins (blue square). The 
hapten–protein complex is recognized as foreign by APCs which take up and process the hapten–protein complex producing a pool of drug modified peptides (yellow triangle 
and blue triangle). The drug modified peptide is presented in association with MHC and is recognized by the TCR as a neoantigen and activates the immune response. (B) 
In the PI model the drug (yellow star) is able to bind noncovalently to either the TCR or MHC leading to activation of the immune system. (C) In the altered self-peptide 
repertoire model, the drug (yellow star) binds to the antigen binding cleft of the MHC. This results in presentation of novel peptides (green triangle) to the TCR and activation 
of the immune system.
Abbreviations: APC, antigen processing cell; MHC, major histocompatibility complex; PI, direct pharmacologic interaction of drugs with immune receptors; TCR, T-cell 
receptor.
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with MPE were included in the second review. In the third 
systematic review, carriage of HLA-A*31:01 was reported 
to increase the risk of CBZ-induced HSS in Caucasian and 
Japanese/Korean patients by 14- and 10-fold, respectively.44 
Susceptibility to all phenotypes of CBZ hypersensitivity was 
increased by 7-fold in Caucasians and 8-fold in Japanese 
patients positive for HLA-A*31:01.44
Estimates for sensitivity, specificity, positive predictive 
value, negative predictive value (NPV) and the number needed 
to test (NNT) to prevent a CBZ hypersensitivity reaction have 
been generated from the two large GWAS (Table 3).7,8 In Japa-
nese patients, the NNT to prevent one CBZ hypersensitivity 
reaction is 67 based on an incidence of CBZ hypersensitivity 
reaction of 2.9%.8 The incidence of CBZ hypersensitivity in 
European patients was estimated to be 10%1 meaning the NNT 
to prevent one case of CBZ hypersensitivity in Caucasians is 
47.3 In Han Chinese patients, HLA-A*31:01 was significantly 
associated with CBZ-induced HSS.22 The NNT was 5000 in 
order to prevent one case of HSS as the incidence of CBZ-
induced HSS was estimated as 0.05%.22
A single study has examined the cost-effectiveness of 
pharmacogenetic screening for HLA-A*31:01 prior to the 
initiation of CBZ therapy in the UK.45 The authors concluded 
that routine testing for HLA-A*31:01 in order to reduce the 
incidence of hypersensitivity reactions in patients being 
prescribed CBZ for epilepsy is likely to be cost-effective. 
The cost-effectiveness model predicted a reduction in cases 
from 780 to 700 per 10,000 patients with an incremental cost-
effectiveness ratio of £12,808 per quality-adjusted life-year 
(QALY) gained, which is below the threshold used by the UK 
National Institute for Health and Care Excellence to judge 
cost-effectiveness (£20,000–30,000/QALY).
A study of patient and physician expectations of pharma-
cogenetic testing prior to CBZ therapy revealed that patients 
were willing to accept a less effective anticonvulsant drug 
if the treatment had less risk of harm; whereas neurologists 
placed emphasis on higher NPVs for pharmacogenetic 
testing in order to reduce the likelihood of false negative 
tests.46 Based on actual rates of CBZ hypersensitivity and the 
characteristics of HLA-A*31:01 testing, patients preferred 
testing and  prescription of an alternative anticonvulsant, 
such as lamotrigine (conditional on test result) compared 
with current standard of care (no pharmacogenetic testing).
Although the majority of hypersensitivity reactions 
with CBZ present as the milder MPE phenotype; it is not 
possible to distinguish the patients who will progress from 
MPE to the more severe systemic and blistering conditions. 
Therefore, patients are currently advised to stop CBZ on first 
occurrence of cutaneous eruption because early discontinu-
ation of culprit drug reduces the risk of progression to more 
severe disease and death.47 Patients who test positive for 
HLA-A*31:01 can be prescribed alternative antiepileptic 
drug (AED) therapy, such as lamotrigine, which has not been 
associated with hypersensitivity in HLA-A*31:01 carriers.48 
In patients positive for HLA-A*31:01 who still require CBZ 
therapy, for example, when alternative treatments have failed 
or are unavailable, pharmacogenetics testing can still help 
alert clinicians to patients at greater risk of hypersensitivity 
and to monitor these patients more closely.
One study has explored the potential for using a combined 
HLA-A*31:01 and HLA-B*15:02 pharmacogenetic test to 
prevent CBZ hypersensitivity in a Han Chinese population.22 
Using a combined test, the NNT to prevent one case was 455 
with 94 out of 1000 patients being unnecessarily denied CBZ. 
The potential clinical utility and cost-effectiveness of the com-
bined test will need to be evaluated in further clinical studies.
If pretreatment testing for HLA-A*31:01 is adopted into 
clinical practice it is important that physicians receive edu-
cation regarding pharmacogenetic testing. In Hong Kong, 
introduction of HLA-B*15:02 testing led to the unintended 
consequence of reduction in the prescription of CBZ from 
16.2% to 2.6% of all new AEDs, with a switch to other 
AEDs such as phenytoin and lamotrigine, which are also 
associated with SJS-TEN.49 Thus, while the incidence of 
CBZ-induced SJS-TEN decreased in those patients tested 
for HLA-B*15:02, the overall incidence of SJS-TEN did not 
change, as patients were put on other drugs associated with 
SJS-TEN, where no recommendation for HLA screening has 
been mandated (because no strong HLA associations have 
been demonstrated). It is known that there is cross-reactivity 
Table 3 Characteristics for HLA-A*31:01 pharmacogenetic screening test in CBZ hypersensitivity
Population Phenotype Sensitivity (%) Specificity (%) PPV (%) NPV (%) NNT References
Caucasian All 26 96 43 92 47a 7
Japanese All 58 87 12 99 67b 8
Han Chinese HSS 50 98.5 0.59 100 5000c 22
Notes: aIncidence of CBZ hypersensitivity among Caucasians estimated at 10%. bIncidence of CBZ hypersensitivity among Japanese estimated at 2.9%. cIncidence of CBZ-HSS 
in Han Chinese estimated at 0.05%.
Abbreviations: CBZ, carbamazepine; HSS, hypersensitivity syndrome; NNT, number needed to test in order to avoid one case; NPV, negative predictive value; PPV, 
positive predictive value.
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between different aromatic anticonvulsants, such as phe-
nytoin, where a weaker association between SJS/TEN and 
HLA-B*15:02 has been reported.50
The Canadian Pharmacogenomics Network for Drug 
Safety recommend pharmacogenetic testing for HLA-
A*31:01 before initiation of CBZ in patients of all ancestries 
to reduce the incidence of hypersensitivity reactions. It also 
recommends testing in patients who have had a previous 
hypersensitivity reaction where CBZ may have been the 
culprit drug or where reinitiation of CBZ is being considered. 
A positive test would increase the likelihood of the previous 
hypersensitivity reaction being related to CBZ.44
Conclusion
There is no doubt that there is an association between HLA-
A*31:01 and CBZ hypersensitivity, in particular to HSS, in 
many different ethnic groups. This association may also be 
relevant for MPE, but the association is confounded by the 
fact that causality can be due to other factors, which are not 
easily distinguished from CBZ. There is also an association 
with SJS-TEN, albeit weaker than with HSS, in many popu-
lations, but not in South East Asians, where the prevalent 
HLA-B*15:02 allele has an extremely strong association 
with CBZ-induced SJS-TEN. It is important to stress that the 
association with HLA-B*15:02 is limited to CBZ-induced 
SJS-TEN, whereas the association with HLA-A*31:01 may 
be important for all CBZ hypersensitivity phenotypes,3 but 
the molecular mechanisms and pathways underlying these 
distinct clinical manifestations are unclear.
Currently, the CBZ label/SmPC mandates testing for 
HLA-B*15:02 before the use of CBZ in certain ethnic groups, 
but mentions HLA-A*31:01 for information only (Figure 3). 
Arguably, this could be considered to be appropriate in regu-
latory terms because 1) the association with HLA-B*15:02 
and an immune-mediated reaction with CBZ is stronger 
than that seen with HLA-A*31:01;3 2) it prevents the most 
serious reaction associated with CBZ (i.e., SJS-TEN); and 
3) the importance of pre-prescription genotyping has been 
shown in a prospective study.16 Conversely, there are also 
arguments in favor of harmonizing the SmPC for CBZ to 
mandate pre-prescription genetic testing for all patients 
for both HLA-B*15:02 and HLA-A*31:01 (in keeping with 
the Canadian Pharmacogenomics Network for Drug Safety 
recommendations).44 These include:
•	 Testing for some groups based on ethnicity while ignoring 
the rest is likely to lead to health inequalities.
•	 The association of HLA-A*31:01 with CBZ hypersen-
sitivity has been replicated in many populations, and it 
is now widely accepted that for precision medicine to 
succeed, we need to look at all forms of evidence, rather 
than relying on the usual paradigm of prospective studies 
or randomized trials.51 The CBZ SmPC (Figure 3) cur-
rently states that “There are insufficient data supporting 
a recommendation for HLA-A*31:01 screening before 
starting CBZ treatment”, but it is not clear what data 
would be regarded as being sufficient.
•	 Testing for HLA-A*31:01 before prescribing CBZ has 
been shown to be cost-effective,45 and at present, there is 
a disconnect between health technology assessment and 
regulatory advice.
•	 There are alternative drugs available for patients who test 
positive for HLA-A*31:01. However, even when CBZ is 
the preferred alternative, a test that shows a patient is posi-
tive for HLA-A*31:01 would allow for closer monitoring 
and stopping the drug quickly when a patient presents 
with signs of hypersensitivity. Our initial study showed 
that application of the test would increase the posttest 
probability to 26% from the current 5% without the test.7
“Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be
screened for HLA-B*1502 as this allele strongly predicts the risk of severe carbamazepine-associated
Stevens-Johnson syndrome” (wording included in section 4.2, posology and method of administration)
“There are some data that suggest HLA-A*31:01 is associated with an increased risk of carbamazepine
induced cutaneous adverse drug reactions including SJS, TEN, DRESS, or less severe AGEP and maculopapular
rash in people of European descent and the Japanese. There are insufficient data supporting a recommendation
for HLA-A*3101 screening before starting carbamazepine treatment. If patients of European descent or Japanese
origin are known to be positive for HLA-A*31:01 allele, the use of carbamazepine may be considered if the benefits
are thought to exceed risks” (wording included in section 4.4, special warnings and precautions for use)
HLA-B*15:02
HLA-A*31:01
Figure 3 A comparison of the wording in the carbamazepine summary of product characteristics approved by the European Medicines Agency for testing for HLA alleles.
Notes: Adapted from Electronic Medicines Compendium website. Available from https://www.medicines.org.uk/emc/medicine/24201.65
Abbreviations: AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; HLA, human leukocyte antigen; SJS, 
Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.
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•	 Although testing for HLA-A*31:01 will largely prevent 
the milder cutaneous reactions, we cannot at present pre-
dict which patients with mild reactions will progress to 
the more serious reactions such as HSS and SJS/TEN, and 
thus by default serious reactions will also be prevented.
Given the above arguments, on balance, we would favor 
that patients starting on CBZ are genotyped for both HLA-
B*15:02 and HLA-A*31:01. The success of this approach will 
depend on the availability of HLA testing, rapid turnaround 
times for the test (so that patients are not kept waiting to 
start their treatment), education of the prescribers, preferably 
accompanied by decision support to enable correct interpre-
tation of the test results, and warnings that avoiding genetic 
testing and prescribing alternatives may have unintended 
consequences as was seen in Hong Kong.49
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